Susceptibility to cephalosporin combinations and aztreonam/avibactam among third-generation cephalosporin-resistant Enterobacteriaceae recovered on hospital admission

International Journal of Antimicrobial Agents

Volumn 49, Issue 2, 2017, Pages 239-242

  Mischnik, Alexander ^a,b   Baumert, Philipp ^a,b   Hamprecht, Axel ^a,c   Rohde, Anna ^a,d   Peter, Silke ^a,e   Feihl, Susanne ^a,f   Knobloch, Johannes ^a,g   Gölz, Hanna ^a,b   Kola, Axel ^a,d   Obermann, Birgit ^a,h   Querbach, Christiane ^a,f   Willmann, Matthias ^a,e   Gebhardt, Friedemann ^a,f   Tacconelli, Evelina ^a,i   Gastmeier, Petra ^a,d   Seifert, Harald ^a,c   Kern, Winfried V ^a,b  

^a Hamburg Luebeck Borstel Insel Riems   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

AmpC; Avibactam; ESBL; Extended spectrum lactamase; Lactam

Indexed keywords

AVIBACTAM; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CLAVULANIC ACID; ERTAPENEM; MEROPENEM; TAZOBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; GERMANY; HOSPITAL; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; AZTREONAM; BETA-LACTAMASE INHIBITORS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; CLAVULANIC ACID; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; GERMANY; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; YOUNG ADULT;

EID: 85008214271     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.10.013     Document Type: Article

References (23)

1. [1] Bush, K., Courvalin, P., Dantas, G., Davies, J., Eisenstein, B., Huovinen, P., et al. Tackling antibiotic resistance. Nat Rev Microbiol 9 (2011), 894–896.
2. [2] Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
3. [3] Livermore, D.M., β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8 (1995), 557–584.
4. [4] Philippon, A., Arlet, G., Jacoby, G.A., Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 46 (2002), 1–11.
5. [5] Bin, C., Hui, W., Renyuan, Z., Yongzhong, N., Xiuli, X., Yingchun, X., et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56 (2006), 351–357.
6. [6] Paterson, D.L., Ko, W.C., Von Gottberg, A., Casellas, J.M., Mulazimoglu, L., Klugman, K.P., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39 (2001), 2206–2212.
7. [7] Hamprecht, A., Rohde, A.M., Behnke, M., Feihl, S., Gastmeier, P., Gebhardt, F., et al. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Antimicrob Chemother 71 (2016), 2957–2963.
8. [8] Giske, C.G., Martinez-Martinez, L., Canton, R., Stefani, S., Skov, R., Glupczynski, Y., et al. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance, v.1.0. EUCAST; Available from: http://www.eucast.org/resistance_mechanisms/, 2013 [Accessed 23 November 2016].
9. [9] Polsfuss, S., Bloemberg, G.V., Giger, J., Meyer, V., Bottger, E.C., Hombach, M., Practical approach for reliable detection of AmpC β-lactamase-producing Enterobacteriaceae. J Clin Microbiol 49 (2011), 2798–2803.
10. [10] Wellinghausen, N., Pietzcker, T., Poppert, S., Belak, S., Fieser, N., Bartel, M., et al. Evaluation of the Merlin MICRONAUT system for rapid direct susceptibility testing of Gram-positive cocci and Gram-negative bacilli from positive blood cultures. J Clin Microbiol 45 (2007), 789–795.
11. [11] Valenza, G., Nickel, S., Pfeifer, Y., Eller, C., Krupa, E., Lehner-Reindl, V., et al. Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 58 (2014), 1228–1230.
12. [12] Karanika, S., Karantanos, T., Arvanitis, M., Grigoras, C., Mylonakis, E., Fecal colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and metaanalysis. Clin Infect Dis 63 (2016), 310–318.
13. [13] Lee, N.Y., Lee, C.C., Li, C.W., Li, M.C., Chen, P.L., Chang, C.M., et al. Cefepime therapy for monomicrobial Enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates. Antimicrob Agents Chemother 59 (2015), 7558–7563.
14. [14] Rhodes, N.J., Richardson, C.L., Heraty, R., Liu, J., Malczynski, M., Qi, C., et al. Unacceptably high error rates in Vitek 2 testing of cefepime susceptibility in extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 58 (2014), 3757–3761.
15. [15] Livermore, D.M., Mushtaq, S., Nguyen, T., Warner, M., Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae. Int J Antimicrob Agents 37 (2011), 405–409.
16. [16] Pal, R.B., Pal, P., Jain, S., Kulkarni, K.P., In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among β-lactamase positive clinical isolates of Gram-positive and Gram-negative pathogens. J Indian Med Assoc 106 (2008), 545–548.
17. [17] Hackel, M., Kazmierczak, K., Hoban, D.J., Biedenbach, D.J., Bouchillon, S.K., de Jonge, B.L., et al. Assessment of the in vitro activity of ceftazidime–avibactam against multidrug-resistant Klebsiella spp. collected in the INFORM Global Surveillance Study, 2012 to 2014. Antimicrob Agents Chemother 60 (2016), 4677–4683.
18. [18] Mutters, N.T., Zimmermann, S., Kaase, M., Mischnik, A., Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. Eur J Clin Microbiol Infect Dis 34 (2015), 2429–2437.
19. [19] Sy, S.K., Beaudoin, M.E., Zhuang, L., Loblein, K.I., Lux, C., Kissel, M., et al. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. J Antimicrob Chemother 71 (2016), 1866–1880.
20. [20] Li, H., Estabrook, M., Jacoby, G.A., Nichols, W.W., Testa, R.T., Bush, K., In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother 59 (2015), 1789–1793.
21. [21] Kaur, R., Gautam, V., Singhal, L., Ray, P., Antimicrobial activity of cefepime–tazobactam combination tested against clinical isolates of Enterobacteriaceae. J Antibiot (Tokyo) 67 (2014), 603–604.
22. [22] Sood, S., Comparative evaluation of the in-vitro activity of six β-lactam/β-lactamase inhibitor combinations against Gram negative bacilli. J Clin Diagn Res 7 (2013), 224–228.
23. [23] Livermore, D.M., Mushtaq, S., Warner, M., Woodford, N., WCK 4282 (high-dose cefepime–tazobactam) against multi-resistant Gram-negative bacteria. In: 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 9–12 April 2016; Amsterdam, The Netherlands. Basel, Switzerland: ESCMID, 2016 [poster P1265].